MUTATIONAL STATUS AND SOME CLINICO-MORPHOLOGICAL FEATURES OF CUTANEOUS MELANOMA
- Authors: Mazurenko N.N1, Tsyganova I.V1, Lushnikova A.A1, Anurova O.A1, Ponkratova D.A1, Vikhrova A.N1, Utyashev I.A1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- Issue: Vol 22, No 2 (2017)
- Pages: 60-65
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40339
- DOI: https://doi.org/10.18821/1028-9984-2017-22-2-60-65
- ID: 40339
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
N. N Mazurenko
N.N. Blokhin Russian Cancer Research Center
Email: nnmazurenko@mail.ru
д-р биол. наук, проф., заведующая лабораторией онкогеномики НИИ канцерогенеза. Moscow, 115478, Russian Federation
I. V Tsyganova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
A. A Lushnikova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
O. A Anurova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
D. A Ponkratova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
A. N Vikhrova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
I. A Utyashev
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
References
- Мазуренко Н.Н. Молекулярно-генетические факторы и маркеры меланомы. В кн: Кушлинский Н.Е., Мазуренко Н.Н., Немцова М.В. (ред.) Молекулярно-генетические маркеры опухолей. М.: Издательство РАМН; 2016: 85-128.
- Rajkumar S., Watson I.R. Molecular characterization of cutaneous melanoma: creating a framework for targeted and immune therapies. Br. J. Cancer. 2016; 115(2): 145-55.
- Статистика злокачественных новообразований в России и странах СНГ в 2013 году / Под ред. М.И. Давыдова, Е.М. Аксель. М.; 2015: 217.
- Chakraborty R., Wieland C.N., Comfere N.I. Molecular targeted therapies in metastatic melanoma. Pharmacogen. Person. Med. 2013; 6: 49-56.
- Grimaldi A.M., Simeone E., Festino L. et al.Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. Discovery Med. 2015; 19(107): 455-61.
- Bello D.M., Ariyan C.E., Carvajal R.D. Melanoma mutagenesis and aberrant cell signaling. Cancer Control. 2013; 20(4): 261-81.
- Platz A., Egyhazi S., Ringborg U., Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol. Oncol. 2008; 1(4): 395-405.
- Ellenrhorst J., Greene V.R., Ekmekcioglu S. Warneke C.L., Johnson M.M., Xoopr C.P. et al. Clinical correlations of NRAS and BRAF mutations in primary human melanoma. Clin. Cancer Res. 2011; 17(2): 229-35.
- Tschandi P., Berghoff A.S., Preusser M., Burgstaller-Muehlbacher S., Pehamberger H., Okamoto I. et al. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS One. 2013; 8(7): e69639.
- Ascierto P.A., McArthur G.A., Dréno B., Atkinson V., Liszkay G., Di Giacomo A.M. et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016; 17(9): 1248-60. doi: 10.1016/S1470-2045(16)30122-X
- Vennepureddy A., Thumallapally N., Motilal Nehru V., Atallah J.P., Terjanian T. Novel drugs and combination therapies for the treatment of metastatic melanoma. J. Clin. Med. Res. 2016; 8(2): 63-75. doi: 10.14740/jocmr2424w
- Мазуренко Н.Н., Цыганова И.В., Лушникова А.А., Понкратова Д.А., Анурова О.А., Черемушкин Е.А. и др. Спектр мутаций онкогенов различается в подтипах меланомы кожи. Молекул. биол 2015; 59(6): 1022-9.
- Франк Г.А., Завалишина Л.Э., Кекеева Т.В., Алексахина С.Н., Гарифуллина Т.Р., Иванцов О.А. и др. Первое Всероссийское молекулярно-эпидемиологическое исследование меланомы: результаты анализа мутаций в гене BRAF. Арх. пат. 2014, (3): 65-72.
- Jakob J.A., Bassett R.L.Jr., Ng C.S., Curry J.L., Joseph R.W., Alvarado G.C. et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012; 118(16): 4014-23.
- Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S. et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949-54.
- Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M. et al. Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116(6): 855-67.
- Bowyer S.E., Rao A.D., Lyle M., Sandhu S., Long G.V., McArthur G.A. et al. Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res. 2014; 24(5): 504-8.
- Ross A.L., Sanchez M.I., Grichnik J.M. Molecular nevogenesis. Dermatol. Res. Pract. 2011. 463184. doi: 10.1155/2011/463184.
- Fedorenko I.V., Gibney G.T., Keiran S.M. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 2013; 32(25): 3009-18.